Skip to main content
The effects of preoperative renin-angiotensin system inhibitors on outcomes in patients undergoing cardiac surgery.
- Author(s): Shi, Pengcai;
- Li, Zhongmin;
- Young, Nilas;
- Ji, Fuhai;
- Wang, Yuelan;
- Moore, Peter;
- Liu, Hong
- et al.
Published Web Locationhttps://doi.org/10.1053/j.jvca.2013.01.012
ObjectiveThe effects of preoperative (pre-op) renin-angiotensin system (RAS) inhibitors on outcomes in patients undergoing cardiac surgery remain uncertain. The aim of this study was to evaluate whether the use of pre-op RAS inhibitors affected major outcomes of cardiac surgery.
DesignA retrospective cohort study.
SettingA university teaching hospital.
ParticipantsPatients undergoing cardiac surgery between January 1, 2001 and December 31, 2011.
InterventionsOne thousand two hundred thirty-nine patients who received pre-op RAS inhibitors were compared with those who did not (control group, n = 1,083).
Measurements and main resultsAcute kidney injury (AKI) was defined using Acute Kidney Injury Network classification. Patients in the RAS inhibitors group presented with higher comorbidities. Pre-op RAS inhibitors therapy was associated with the reduction in the incidence of AKI (27.2% v 34.0%, p<0.001), septicemia (1.9% v 3.5%, p = 0.019), and operative mortality (2.99% v 4.62%, p = 0.039). After adjusted propensity scores and multivariate logistic regression, the pre-op RAS inhibitors were found to have protective effects against AKI (odds ratio [OR]: 0.764, 95% confidence interval [CI]: 0.670-0.873, p<0.001), septicemia (OR: 0.515, 95% CI: 0.348-0.761, p>0.001), and operative mortality (OR: 0.539, 95% CI: 0.348-0.758, p<0.001).
ConclusionThe results suggested that pre-op RAS inhibitor therapy was associated with significant reductions in the risk of AKI, operative mortality, and septicemia.
For improved accessibility of PDF content, download the file to your device.